The Latest Clinical Considerations for Non-Small Cell Lung Cancer: A Global Approach

The Latest Clinical Considerations for Non-Small Cell Lung Cancer: A Global Approach

The Latest Clinical Considerations for Non-Small Cell Lung Cancer: A Global Approach
RestartResume

Keep up with rapidly evolving data on the use of immunotherapies in advanced NSCLC and discover regional differences across countries and continents.

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Are dMMR and MSI-H both markers that will soon replace or work in conjunction with PD-L1 when determining immunotherapy for patients with metastatic NSCLC? Accurate testing and treatment selection is critical in identifying patients who will benefit from these therapies. Dr. Federico Cappuzzo, Dr. Solange Peters, and Professor Yi-Long Wu discuss emerging data from the recent WCLC, ESMO, and ASCO virtual conferences and offer their international and regional perspectives on the evolving use of immunotherapies in advanced NSCLC.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Federico Cappuzzo
    Director Medical Oncology
    NCI Regina Elena
    Rome, Italy

    Consulting Fees: Merck Sharp and Dohme

    Faculty:
    Professor Solange Peters
    Chair Medical Oncology
    Oncology Department – CHUV
    Lausanne, Switzerland

    Consulting Fees: Merck Sharp and Dohme
    Speakers Bureau: Merck Sharp and Dohme
    Contracted Research: Merck Sharp and Dohme

    Professor Yi-Long Wu
    Guangdong Lung Cancer Institute
    Guangdong Provincial People’s Hospital
    Guangzhou, China

    Speakers Bureau: Merck Sharp and Dohme

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Ann Early has nothing to disclose.
    • William A. Mencia, MD, FACEHP, CHCP has nothing to disclose.
    • Brian P. McDonough MD, FAAFP has nothing to disclose.
    • Tricia O’Leary has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Evaluate the most recent evidence from clinical trials on the effectiveness and safety of immunotherapies for metastatic NSCLC
    • Distinguish how clinical practice guidelines used in Europe and China differ from the latest data for immunotherapies for metastatic NSCLC
    • Describe best practices for biomarker testing to guide treatment decisions for patients with metastatic NSCLC
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, pathologists, and pulmonologists.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    ReachMD Healthcare Image

    AGILE - Academy for Interprofessional Learning and Education - designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions.  Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes

  • Commercial Support

    This activity is supported by an independent educational grant from Merck

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and AGILE This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of AGILE you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

    Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement”. 

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free